Market Overview

Needham Says Buy the Dip in Isis Pharma, Didn't See Favorable Chance CRP Would Be Indicated for RA

Related ISIS
Aegerion Shares Up on Study Initiation - Analyst Blog
Isis Reports Final Phase 2 Data on ISIS-APOCIII Rx

Shares of Isis Pharma (NASDAQ: ISIS) have fallen nearly 3 percent Monday as the company announced it has halted development of its rheumatoid arthritis product as the latest study failed to demonstrate a benefit.

Needham analyst Chad Messer issued a research note earlier suggesting investors should use the dip in price to load up on shares. Messer pointed out he didn't consider the RA drug as a "serious consideration" for the company's ISIS-CRP. He believes the next catalyst for APOCIII monotherapy trial is later in August.

Needham maintains a Buy rating and $36 price target on shares of Isis Pharma.

Posted-In: Analyst Color News FDA Analyst Ratings

 

Most Popular

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free